UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Has $30.87 Million Stake in Insmed Incorporated (NASDAQ:INSM)

UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC lowered its holdings in Insmed Incorporated (NASDAQ:INSM - Free Report) by 65.8% during the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 422,936 shares of the biopharmaceutical company's stock after selling 814,319 shares during the quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC owned 0.24% of Insmed worth $30,874,000 at the end of the most recent quarter.

Several other hedge funds have also recently added to or reduced their stakes in the business. V Square Quantitative Management LLC bought a new position in shares of Insmed during the third quarter valued at $30,000. GAMMA Investing LLC boosted its position in Insmed by 71.3% in the third quarter. GAMMA Investing LLC now owns 538 shares of the biopharmaceutical company's stock valued at $39,000 after buying an additional 224 shares in the last quarter. First Horizon Advisors Inc. grew its stake in Insmed by 83.4% during the second quarter. First Horizon Advisors Inc. now owns 631 shares of the biopharmaceutical company's stock worth $42,000 after buying an additional 287 shares during the last quarter. Exchange Traded Concepts LLC grew its stake in Insmed by 522.5% during the third quarter. Exchange Traded Concepts LLC now owns 747 shares of the biopharmaceutical company's stock worth $55,000 after buying an additional 627 shares during the last quarter. Finally, CWM LLC increased its holdings in shares of Insmed by 11.0% during the second quarter. CWM LLC now owns 1,570 shares of the biopharmaceutical company's stock worth $105,000 after buying an additional 155 shares in the last quarter.

Insider Buying and Selling

In other news, insider Orlov S. Nicole Schaeffer sold 37,575 shares of the stock in a transaction dated Tuesday, September 10th. The shares were sold at an average price of $71.50, for a total transaction of $2,686,612.50. Following the completion of the transaction, the insider now directly owns 100,100 shares in the company, valued at $7,157,150. This represents a 27.29 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Also, insider Michael Alexander Smith sold 27,871 shares of Insmed stock in a transaction dated Friday, September 13th. The shares were sold at an average price of $74.35, for a total value of $2,072,208.85. Following the completion of the sale, the insider now directly owns 67,856 shares in the company, valued at approximately $5,045,093.60. This represents a 29.12 % decrease in their position. The disclosure for this sale can be found here. Over the last three months, insiders sold 78,882 shares of company stock worth $5,765,446. 4.60% of the stock is owned by corporate insiders.

Insmed Stock Down 0.0 %

Shares of INSM stock traded down $0.03 during trading hours on Thursday, hitting $75.33. 2,244,301 shares of the company were exchanged, compared to its average volume of 2,215,028. Insmed Incorporated has a 52 week low of $21.92 and a 52 week high of $80.53. The company has a current ratio of 6.37, a quick ratio of 5.99 and a debt-to-equity ratio of 2.03. The business has a 50 day moving average of $72.31 and a two-hundred day moving average of $69.10. The company has a market capitalization of $13.48 billion, a PE ratio of -13.57 and a beta of 1.10.

Insmed (NASDAQ:INSM - Get Free Report) last released its earnings results on Thursday, October 31st. The biopharmaceutical company reported ($1.27) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($1.19) by ($0.08). The business had revenue of $93.40 million during the quarter, compared to analysts' expectations of $93.36 million. During the same period in the previous year, the business posted ($1.10) EPS. The company's quarterly revenue was up 18.1% on a year-over-year basis. Analysts anticipate that Insmed Incorporated will post -5.44 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

A number of equities research analysts recently commented on the company. Cantor Fitzgerald restated an "overweight" rating on shares of Insmed in a research report on Monday, September 9th. StockNews.com cut Insmed from a "hold" rating to a "sell" rating in a report on Friday, August 9th. Truist Financial restated a "buy" rating and issued a $105.00 target price (up from $100.00) on shares of Insmed in a research note on Friday, November 1st. JPMorgan Chase & Co. upped their price target on shares of Insmed from $74.00 to $83.00 and gave the stock an "overweight" rating in a research report on Friday, November 22nd. Finally, Bank of America raised their price objective on shares of Insmed from $84.00 to $86.00 and gave the company a "buy" rating in a research report on Wednesday, October 9th. One analyst has rated the stock with a sell rating and sixteen have issued a buy rating to the company. Based on data from MarketBeat, the stock presently has an average rating of "Moderate Buy" and a consensus target price of $83.67.

Insmed Company Profile

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed's first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options.